Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

Cladribine (2-chlorodeoxyadenosine, 2CdA) is one of the most effective disease-modifying drugs for multiple sclerosis (MS). Cladribine is a synthetic purine nucleoside analog that induces cell death of lymphocytes and oral cladribine treatment leads to a long-lasting disease stabilization, potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Medeiros-Furquim, Tiago, Ayoub, Sinan, Johnson, Laura J., Aprico, Andrea, Nwoke, Eze, Binder, Michele D., Kilpatrick, Trevor J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207174/
https://www.ncbi.nlm.nih.gov/pubmed/35734180
http://dx.doi.org/10.3389/fimmu.2022.678817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207174/
https://www.ncbi.nlm.nih.gov/pubmed/35734180
http://dx.doi.org/10.3389/fimmu.2022.678817

Ejemplares similares